News Home

Where Will Pfizer Inc. (PFE) Stock Go Next After It Has Fallen 3.47% in a Week?

Wednesday, September 01, 2021 02:15 PM | InvestorsObserver Analysts
Where Will Pfizer Inc. (PFE) Stock Go Next After It Has Fallen 3.47% in a Week?

Pfizer Inc. (PFE) stock is down 3.47% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
Pfizer Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PFE!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With PFE Stock Today?

Pfizer Inc. (PFE) stock has fallen -0.46% while the S&P 500 has risen 0.29% as of 2:06 PM on Wednesday, Sep 1. PFE is down -$0.21 from the previous closing price of $46.07 on volume of 21,707,823 shares. Over the past year the S&P 500 is higher by 29.59% while PFE has risen 28.10%. PFE earned $2.34 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 19.61.

More About Pfizer Inc.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Click Here to get the full Stock Report for Pfizer Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App